Medicago was a Quebec biopharmaceutical company known for plant-based virus-like particle vaccine technology. The company developed COVIFENZ, a plant-derived COVID-19 vaccine, and built its platform around using plants as bioreactors to produce vaccine and protein candidates. Although Medicago’s operations were terminated in 2023, it remains notable in Canadian biotech for advancing plant-based vaccine manufacturing.